Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal